Revance Reports Second Quarter 2021 Financial Results, Provides Corporate Update
Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, today reported financial results for the second quarter ended June 30, 2021 and provided a corporate update.
- Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, today reported financial results for the second quarter ended June 30, 2021 and provided a corporate update.
- Revenue for the second quarter 2021 totaled $18.8 million compared to $0.3 million for the second quarter 2020.
- Fintech payment processing volume run-rate increased to over $500 million in the second quarter 2021.
- Revance Therapeutics and the Revance logo are registered trademarks of Revance Therapeutics, Inc.
Resilient Hyaluronic Acid and RHA are trademarks of TEOXANE SA.